Dare Bioscience, Inc. quarterly report, Q3 FY2015

Business context and reporting period

Important identity discrepancy: The request identifies Dare Bioscience, Inc., but the supplied Form 10-Q is for Cerulean Pharma Inc. This summary covers Cerulean’s quarter and nine months ended September 30, 2015; the filing was signed November 16, 2015.

Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates. Its lead candidate, CRLX101, was in Phase 2 development, and CRLX301 was in Phase 1. The company had no product sales and expected no product revenue for several years, if ever.

Financial results and liquidity

MetricQ3 2015Q3 2014Nine months 2015Nine months 2014
Revenue$0$0$0$80,000
Research and development$7.092 million$2.928 million$18.791 million$7.071 million
General and administrative$2.954 million$2.441 million$8.352 million$5.980 million
Operating expenses$10.046 million$5.369 million$27.143 million$13.051 million
Net loss$10.551 million$5.558 million$28.886 million$15.875 million
Basic and diluted loss per share$0.39$0.28$1.17$1.26

At September 30, 2015, cash and cash equivalents were $77.631 million, total current assets $79.153 million, and total current liabilities $10.608 million. The balance sheet reported loan payable of $14.561 million in total ($4.031 million current and $10.530 million long-term), plus $0.336 million non-current accrued interest. No meaningful product gross margin was reported because the company had no product revenue.

For the first nine months, operating cash use was $23.705 million, investing cash use $0.371 million, and financing cash provided $50.533 million. Cash increased $26.457 million from $51.174 million at year-end 2014. Financing included $37.185 million net from the April 2015 public offering and $15 million of Hercules loan proceeds; the company also repaid $3.921 million of loans.

Material changes versus prior comparable periods

  • Year-to-date net loss rose 82% to $28.886 million, primarily as research and development spending increased 166%, reflecting advancement of CRLX101 and CRLX301 trials and related manufacturing activity.
  • Q3 research and development increased 142% year over year; CRLX101 accounted for $5.114 million of Q3 spending, up 230%.
  • Year-to-date interest expense increased to $1.751 million from $0.920 million. Prior-year other expense included a $2.493 million debt-extinguishment loss, so total other expense was lower in 2015 despite higher interest expense.
  • Shares issued and outstanding increased to 27,346,780 from 20,125,049 at December 31, 2014, reflecting the April 2015 offering and other share activity. The filing notes this affects loss-per-share comparability.

Outlook, commentary, and risks

  • Management said September 30 cash was expected to fund operating expenses, debt service, and capital expenditures into 2017, but cautioned this estimate depends on assumptions that could prove wrong. The company expected significant future losses and said it would need additional capital.
  • In October, Cerulean reported completing enrollment of 115 patients in its randomized Phase 2 CRLX101/Avastin renal-cell-carcinoma trial; results were not reported. In an ovarian-cancer investigator-sponsored trial, nine of 16 evaluable patients reportedly had at least six months of progression-free survival as of November 12; two additional patients had not yet reached six months. These were interim, preliminary observations.
  • CRLX101 received FDA fast-track designation for certain metastatic renal-cell-carcinoma patients; the FDA also granted orphan-drug designation for ovarian cancer. The filing cautions that such designations do not assure faster review or approval.
  • The Hercules facility had a $15 million initial borrowing and up to $11 million in additional conditional tranches. Further borrowing depended on clinical, financing, and other conditions; debt was secured by substantially all assets other than intellectual property, which was subject to a negative pledge. The loan matured July 1, 2018 and had a stated minimum floating rate of 7.30%, with a 6.7% end-of-term charge on original principal advanced.
  • A new 22,992-square-foot Waltham lease was due to commence December 28, 2015 and expire February 28, 2021. Annual base rent was $689,760 in each of the first two years, plus operating expenses, utilities, and taxes.
  • Key risks include clinical-trial failure or delay, uncertain regulatory approval and commercialization, reliance on third-party manufacturers and investigator-sponsored trials, potential future financing needs and dilution, competition, and intellectual-property and licensing risks. The filing also describes Calando’s bankruptcy and possible effects on licensed rights.

Important facts for investors to verify

  1. Confirm the issuer: the supplied filing is Cerulean Pharma Inc., not Dare Bioscience, Inc.
  2. Check the underlying clinical-trial updates and denominators for the preliminary CRLX101 ovarian results, and monitor for complete data from the fully enrolled renal-cell-carcinoma trial.
  3. Verify whether the company met the Hercules loan’s clinical and financing conditions for additional tranches and assess the debt’s full repayment costs and collateral terms.
  4. Assess cash runway against actual clinical, manufacturing, lease, and debt-service spending; management’s runway estimate was expressly assumption-dependent.
  5. Reconcile narrative figures with the financial statements: the filing gives accumulated deficit as $150.667 million on the balance sheet but approximately $150.4 million in the overview, and describes nine-month net loss as approximately $28.6 million in MD&A versus $28.886 million in the statements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.